Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Adlai Nortye Ltd. Sponsored ADR ( (ANL) ) has shared an update.
On April 16, 2026, Adlai Nortye announced it had entered a securities purchase agreement for an oversubscribed private investment in public equity financing expected to raise about $150 million in gross proceeds. The round, priced at $13.25 per ADS, matching the April 15 Nasdaq close, drew participation from a mix of new and existing specialist healthcare and institutional investors.
The company will issue 11,320,755 ADSs in the private placement, which is scheduled to close on April 17, 2026, subject to customary conditions. The transaction, supported by several prominent placement agents, strengthens Adlai Nortye’s balance sheet as it advances its RAS-targeting pipeline and ADC platform, potentially reinforcing its competitive position in the oncology biotech space.
The most recent analyst rating on (ANL) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Adlai Nortye Ltd. Sponsored ADR stock, see the ANL Stock Forecast page.
More about Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. is a global clinical-stage biotechnology company focused on developing innovative cancer therapies. Leveraging R&D operations in the U.S. and China, it is building a pipeline centered on RAS-targeting therapies, including oral and antibody-drug conjugate candidates, as well as next-generation immuno-oncology drugs designed to modulate PD-L1 and T-cell activity.
Average Trading Volume: 692,158
Technical Sentiment Signal: Buy
Current Market Cap: $530M
For detailed information about ANL stock, go to TipRanks’ Stock Analysis page.